Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients

Part of paid clinical trials in Los Angeles, California.

Sponsor
University of California, Los Angeles
Study ID
NCT02321930
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This proposal will evaluate if musculoskeletal ultrasound (MSUS) measures or multi-biomarker disease activity (MBDA) improve in patients treated with tofacitinib over 3 months, and whether early MSUS measures/MBDA can predict response to therapy.

Key Dates

Start date
Feb 16, 2016
Status verified
Feb 2019
Primary completion
Sep 29, 2017
Completion
Sep 29, 2017

Study Design

Enrollment
37 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: tofacitinib 5mg po bid
    Open label with tofacitinib 5mg po bid

Primary Outcome Measure

PDUS [ Time Frame: Baseline, Week 2, Month 3 ]

Locations (1)

FacilityCityStateZIPSite coordinators
UCLA David Geffen School of Medicine, Division of RheumatologyLos AngelesCalifornia90095-

Find similar trials in Los Angeles, CA

By condition
Rheumatoid arthritis
By specialty
RheumatologyAutoimmune diseaseMusculoskeletal disorders
By research site
UCLA David Geffen School of Medicine, Division of Rheumatology· Los Angeles, CA

Related Studies